As part of The Guardian’s Innovations in Oncology and Imaging series, our Chairman and Co-Founder Professor Sir Chris Evans OBE, and our CMO Professor Tobi Arkenau explain how our unique and disruptive drug development model is accelerating the development of potential new cancer treatments.
To read the full article at healthawareness.co.uk, please click here.
